Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received January 19, 2012
- Accepted April 10, 2012
- First Published July 25, 2012.
Article Versions
- Previous version (July 25, 2012 - 13:03).
- You are viewing the most recent version of this article.
Author Disclosures
- Kejal Kantarci, MD, MS,
- Tanis J. Ferman, PhD,
- Bradley F. Boeve, MD,
- Stephen D. Weigand, MS,
- Scott Przybelski, BS,
- Prashanthi Vemuri, PhD,
- Melissa M. Murray, PhD,
- Matthew L. Senjem, MS,
- Glenn E. Smith, PhD,
- David S. Knopman, MD,
- Ronald C. Petersen, MD, PhD,
- Clifford R. Jack Jr., MD,
- Joseph E. Parisi, MD and
- Dennis W. Dickson, MD
- Kejal Kantarci, MD, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
R01 AG040042 (PI); 2011-2016, R21 NS066147 (PI); 2010- 2012, Mayo Clinic Alzheimer’s Disease Research Center/Project 1 P50 AG16574/P1 (PI); 2009-2014, and R01 AG11378 (Co-I);2008-2013
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tanis J. Ferman, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NIA R01 AG15866, Principal Investigator 2005-2010 NIH/NIA P50AG16574, Co-investigator 2005-present NINDS P50NS072187, Co-investigator 2010-present Mangurian Foundation for Lewy body dementia research, Co- Investigator 2010-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bradley F. Boeve, MD,
NONE
NONE
NONE
NONE
NONE
Behavioral Neurology Of Dementia, Cambridge Univeristy Press, 2009
NONE
NONE
NONE
NONE
NONE
Grant support as an investigator in clinical trials funded by; Cephalon, Inc., 2009-present; Allon Therapeutics, Inc., 2010-present; and; GE Healthcare, 2012-present.
National Institute on Aging [P50 AG016574 (Co- Investigator, 2009-present), U01 AG006786 (Co- Investigator, 2009-present), RO1 AG032306 (Co- Investigator, 2010-present); Center for Inherited Disease Research [U24 AG026395 (Co-Investigator, 2009-2011)
NONE
Alzheimer’s Association, 2009; Mangurian Foundation, 2011-present
NONE
NONE
NONE
NONE
NONE
NONE
- Stephen D. Weigand, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Scott Przybelski, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Prashanthi Vemuri, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Melissa M. Murray, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matthew L. Senjem, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Glenn E. Smith, PhD,
1) University of Wisconsin Alzheimer’s Disease Center External Advisory Board (non-profit) 2009-present. Honoraria
NONE
International Congress on Alzheimer Disease (Alzheimer’s Assn/Non-profit, travel funds only 2010 and 2011).
1) Then Clinical Neuropsychologist (2008-current) 2) Journal of International Neuropsychological Society (2008-2010)
NONE
NONE
NONE
1) Homeinstead Senior Living Inc (commercial) Consulted on their staff dementia training program. 2011
NONE
NONE
NONE
NONE
National Center for Research Resources Rizza (PI) U54 RR 24150 Mayo Clinic Center for Clinical and Translational Research Co-investigator, Chair, Post- doctoral programs, Leader of Behavioral Sciences core National Institute on Aging (Co-PI) 5/04 – 4/14 AG16574 Information Transfer Core, Mayo Clinic Alzheimer’s Disease Research Center.Principal Investigator National Institute on Aging Ferman TA (PI) 10/1/05- 9/30/10AG15866Neuropsychology of Dementia with Lewy Bodies Role: Co-investigator National Institute on Neurological Disease & Stroke Kramer P(PI) Subcontract of NS6-2366-02 Tasks of Executive Function.Role: Site PI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David S. Knopman, MD,
Lilly Pharmaceuticals, Data Safety Monitoring Board
NONE
Lecture, University of Zurich, March 2010; Lecture, University of Montana, October 2010; Lecture, University of Toronto, March 2012
Neurology, Deputy Editor
NONE
NONE
NONE
Janssen Alzheimer Immunotherapy program 3/29/11: honorarium paid to my institution; Merck Alzheimer program 11/5/11 paid to my institution.
NONE
NONE
NONE
Janssen for Alzheimer clinical trial; Forest Laboratories for clinical trial in FTLD with memantine; Baxter Laboratories for Alzheimer Clinical trial
NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer’s Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. NIH R01 AG32306 FTD Neuro-imaging;Initiative. 1U01HL096917-01 ARIC Dementia Study.AG 037551 Chronic Kidney Disease and Cognitive functioning.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ronald C. Petersen, MD, PhD,
Pfizer, Inc., Chair, Data Monitoring Committee ; Janssen Alzheimer Immunotherapy, Chair, Data Monitoring Committee
NONE
NONE
NONE
NONE
Mild Cognitive Impairment,Oxford University Press, 2003
NONE
Elan Pharmaceuticals; GE Healthcare
NONE
Novartis CME lecture
NONE
NONE
National Institute on Aging: U01-AG006786 (PI) (1986-present) P50-AG016574 (PI) (1990-present) R01-AG011378 (Co-I) U01-AG024904 (Co-I) Non-financial disclosures: Chair, Medical and Scientific Advisory Council of national Alzheimer’s Association National Advisory Council on Aging, National Institute on Aging
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Clifford R. Jack Jr., MD,
scientific advisory panels:; Elan; Lilly; GE; Eisai; Janssen; Johnson and Johnson; Bristol Meyer Squibb
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Investigator in clinical trials sponsored by Baxter, Allon, and the National Institute on Aging
NONE
Allon and Baxter, perform MRI related services for clinical trial
RO1 AG11378 PI; U01 AG024904-01 co-I; RO1 AG37551 co-I; 1U01HL096917 co-I; U01 AG032438 co-I
NONE
NONE
NONE
NONE
NONE
NONE
Johnson and Johnson, 2010
NONE
- Joseph E. Parisi, MD and
Food and Drug Administration, Device Panel, Transmissable Spongiform Encephalopathies Advisory Committee, Member, 06/2011 - Present
NONE
NONE
NONE
NONE
Oxford, Principles & Practice of Neuropathology, 2nd ed, 2003
NONE
NONE
NONE
NONE
NONE
NONE
NIH NS32352-13
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dennis W. Dickson, MD
NONE
NONE
NONE
Editorial board member of: American Journal of Pathology, Journal of Neuropathology and Experimental Neurology, Brain Pathology, Neurobiology of Aging, Annals of Neurology, Neuropathology, International Journal of Clinical and Experimental Pathology.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
P50-AG25711, P50-AG16574, P50-NS72187, P01-AG17216, P01- AG03949, R01-AG15866
NONE
Cure PSP/Society for PSP
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Radiology (K.K., P.V., M.L.S., C.R.J.) and Neurology (B.F.B., D.S.K., R.C.P.), Department of Health Sciences Research (S.D.W., S.P.), Department of Psychiatry and Psychology (G.E.S.), and Departments of Pathology and Laboratory Medicine (J.E.P.), Mayo Clinic, Rochester, MN; and Department of Psychiatry and Psychology (T.J.F.), Department of Molecular Neuroscience (M.M.M., D.W.D.), and Departments of Pathology and Laboratory Medicine and Neuroscience (D.W.D.), Mayo Clinic, Jacksonville, FL.
- Correspondence & reprint requests to Dr. Kantarci: kantarci.kejal{at}mayo.edu.
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodiesMelissa E. Murray, Tanis J. Ferman, Bradley F. Boeve et al.Neurology, October 09, 2013 -
Article
Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairmentKejal Kantarci, Timothy Lesnick, Tanis J. Ferman et al.Neurology, November 02, 2016 -
Articles
Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodiesT.J. Ferman, B.F. Boeve, G.E. Smith et al.Neurology, August 17, 2011 -
Article
Dementia with Lewy bodiesBasis of cingulate island signJonathan Graff-Radford, Melissa E. Murray, Val J. Lowe et al.Neurology, July 23, 2014